MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Pharmaceutical Executive
August 1, 2011
Jill Wechsler
The Supremes Shape Pharma A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation mark for My Articles similar articles
BusinessWeek
June 10, 2009
Arlene Weintraub
The Fight Over Drug Data Mining Prescription-data collector IMS's legal drama unfolds in a battle over privacy and free speech, and could be headed to the Supreme Court mark for My Articles similar articles
Chemistry World
May 14, 2015
Rebecca Trager
FDA accused of violating drug company's freedom of speech The US Food and Drug Administration is under pressure to reconsider its policy prohibiting pharmaceutical companies from promoting 'off-label' uses of their products. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2011
John F. Brenner
Expanded Liability for Generic, Brand Manufacturers Ahead? To what extent are generics companies obligated by law to request labeling changes with FDA? mark for My Articles similar articles
Reason
July 2005
Who Should Reign Supreme? Libertarian legal experts weigh in on who their favorites are--past, present, and future--on the nation's highest court. mark for My Articles similar articles
The Motley Fool
December 22, 2006
Stephen Albainy-Jenei
Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2014
dos Santos & Leskin
Social Media and the In-House Counsel Social media poses a regulatory and litigation maze that must be carefully navigated by pharmaceutical companies. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. mark for My Articles similar articles
Reason
December 2008
Brian Doherty
How the Second Amendment Was Restored The inside story of how a gang of libertarian lawyers made constitutional history, declaring by a 5-4 decision that yes, the Second Amendment does secure an individual right to keep and bear arms. mark for My Articles similar articles
Home Theater
June 29, 2007
Supreme Court Reconsiders Price Fixing The Supreme Court adopted a looser standard for price fixing yesterday, ruling that manufacturers may sometimes set minimum prices for products without violating antitrust statutes. mark for My Articles similar articles
Salon.com
October 31, 2002
Arianna Huffington
Drugging our children the legal way America's legal drug pushers are free to offer kids their potent concoctions without having to prove they're safe or effective. mark for My Articles similar articles
Salon.com
November 7, 2000
Stephen Cohen
Shameful emissions The Supreme Court weighs whether the EPA overstepped its authority -- and public health hangs in the balance... mark for My Articles similar articles
The Motley Fool
November 4, 2008
Brian Orelli
Does the Supreme Court Control Your Investment? The Supreme Court is about to make a decision that could affect drug company investors. mark for My Articles similar articles
InternetNews
June 29, 2004
Roy Mark
Supreme Court Upholds COPA Ban Justices suggest filtering software superior alternative to content-based restrictions on free speech. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Jill Wechsler
Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007. mark for My Articles similar articles
Reason
August 2002
Jacob Sullum
Second Thoughts John Ashcroft's Second Amendment position, even if adopted by the U.S. Supreme Court, is not likely to have practical consequences anytime soon. mark for My Articles similar articles
The Motley Fool
March 5, 2009
Brian Orelli
The Dilemma for Drugmakers There's no safe place to hide. mark for My Articles similar articles
The Motley Fool
November 22, 2006
Brian Lawler
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. mark for My Articles similar articles
Managed Care
August 2006
Martin Sipkoff
Off-Label Use Often Presents Conundrum for Health Plans Insurers recognize the clinical importance of off-label prescribing, but criteria are needed to avoid over-utilization. mark for My Articles similar articles
Chemistry World
June 6, 2013
Phillip Broadwith
Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud. mark for My Articles similar articles
The Motley Fool
February 22, 2008
Brian Orelli
Supreme Court Gives Health-Care Companies a Boost Medical device maker Medtronic celebrates a Supreme Court ruling in its favor; industry and investors will win in the long term. mark for My Articles similar articles
American History
December 14, 2004
David J. Garrow
The Once and Future Supreme Court The last four decades have witnessed a fundamental transformation in the types of men, and now women, who exercise the broad and untrammeled judicial power of the U.S. Supreme Court. mark for My Articles similar articles
BusinessWeek
October 18, 2004
John Carey
"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be? mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2014
Jill Wechsler
Pre-emption and States' Rights Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Cinquegrana & Lloyd
Legal: Shifting Perspective on Off-Label Promotion A recent court case points to the government's shifting perspective on how it prosecutes companies for promoting off-label. Instead of criminal charges, hefty corporate integrity agreements might be in store. mark for My Articles similar articles
Salon.com
December 11, 2000
Florida Supreme Court clarifies As the U.S. high court hears oral arguments, the Florida court says its ruling was based on state law... mark for My Articles similar articles
Reason
April 2004
Todd Seavey
Regulation for Dummies A book about the FDA. mark for My Articles similar articles
Salon.com
December 13, 2000
Split over the decision Two law professors offer two views of the Supreme Court ruling. Rotunda: The Florida court was acting like a psychic hot line; Raskin: The Supreme Court has disgraced itself... mark for My Articles similar articles
The Motley Fool
December 4, 2007
Brian Orelli
An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2009
Patrick Clinton
Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2012
Jill Wechsler
Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2006
Jill Wechsler
Washington Report: Labels and Liability New FDA guidance aims at better communication of risks. But it creates some, too. mark for My Articles similar articles
Food Processing
August 2013
Eric Lindstrom
FDA Paints Itself Into a Corner with FSMA A federal judge orders the agency to issue overdue food safety rules by November ... which looks unrealistic. mark for My Articles similar articles
BusinessWeek
December 11, 2006
Michael Arndt
Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West. mark for My Articles similar articles
Reason
April 2008
Ronald Bailey
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians. mark for My Articles similar articles
Reason
Aug/Sep 2009
Radley Balko
Just Compensation?: Testing the Takings Clause The Takings Clause in the Fifth Amendment forbids the state from seizing private property for public use without just compensation. mark for My Articles similar articles
Bio-IT World
August 13, 2003
Brian Reid
Remaking the FDA New commissioner is pushing for greater use of technology and innovation to speed the flow of drugs to market. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2006
Richard A. Epstein
FDA vs. the Individual In this excerpt from his important new book Overdose, an ever controversial legal scholar argues that the current system overvalues risk, ignores individual differences, and deprives patients of valuable treatments. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2013
FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2011
Jill Wechsler
The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices. mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2014
Jill Wechsler
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2007
Clinton & Wechsler
The View From Inside Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
Jill Wechsler
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
Jill Wechsler
Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2012
Jill Wechsler
When Talk is Not So Cheap FDA and industry are pushing user fees, while they struggle with curbs on communications. mark for My Articles similar articles
Salon.com
June 16, 2000
Damien Cave
Did Judge Jackson goof? By forcing Microsoft to comply with conduct remedies in 90 days, Jackson may have put the case exactly where he doesn't want it -- in the Court of Appeals. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2006
Jill Wechsler
Washington Report: After Plan B: Out of the Quagmire, into the Data The morning-after pill goes OTC, with some special requirements. But is FDA's drug information system up to the task of tracking how it is used? mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2013
Jill Wechsler
Another Round of FDA Legislation? Pressure for action on key enforcement and regulatory issues may prompt congressional action this year. mark for My Articles similar articles
Chemistry World
May 27, 2015
Phillip Broadwith
Label laundry It's been an interesting month in the world of off-label pharmaceuticals. mark for My Articles similar articles